In this issue:
Broad-based genomic sequencing for NSCLC in the community setting
HCPs’ opinions on lung cancer care in Australia
Dacomitinib for advanced EGFR-mutated NSCLC?
Afatinib + bevacizumab for NSCLC resistant to EGFR TKIs
Osimertinib: CNS efficacy in T790M+ advanced NSCLC
Genetic aberrations and intracranial outcomes in lung adenocarcinoma BMs
PCI vs observation in radically treated stage III NSCLC
Vitamin D supplementation improves survival in resected early-stage NSCLC
Please login below to download this issue (PDF)